Full Press Release Details
Inspira Announces Program
to Pioneer the Applicable Use of the INSPIRA ART100 Device for an Artificial Womb
Ra'anana, Israel, April 03, 2024 -
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a breakthrough
medical technology company, is delighted to announce the commencement of a program to explore the applicable use of the INSPIRA
ART100 Device for an artificial womb for neonates in need of vital respiratory support.
Inspira aims to explore how this potential additional
application of the INSPIRA ART100 device to provide neonates with vital respiratory support could replace the currently used mechanical
ventilators. The high pressure and complications associated with mechanical ventilation can cause harsh and long-term negative effects
on neonates who require respiratory life support during the early and critical stages of their neonatal development. The potential additional
application targets prematurely born neonates with underdeveloped respiratory systems and neonates with life-threatening disorders such
as meconium aspiration syndrome, the disorder that results in neonates experiencing difficulty in breathing as a result of meconium in
the lungs, and congenital diaphragmatic hernia, where the muscle that bisects the chest from the abdomen fails to close.
"Inspira is dedicated to pushing the boundaries of medical technology
to save and improve lives," remarked Dagi Ben-Noon, CEO of Inspira Technologies. "This initiative marks another step
in the journey towards providing safer alternatives to mechanical ventilation. Together, we are targeting to reshape the landscape of
acute neonatal care."
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company
in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed
to rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing
the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The
Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses the aims of the research and development into various potential uses of the INSPIRA ART100 device and the Company's aim
to reshape the landscape of acute neonatal care. These forward-looking statements and their implications are based solely on the current
expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes
no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the
Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year
ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's
website, http://www.sec.gov
Public Relations Manager
Inspira Technologies
Copyright 2018-2024 Inspira Technologies OXY B.H.N. LTD., All